To include your compound in the COVID-19 Resource Center, submit it here.

Natrecor nesiritide: Phase IV; marketed for acutely decompensated heart failure

In the open-label U.S. Phase IV FUSION I trial in 210 patients at high risk for rehospitalization, weekly outpatient infusions of Natrecor were well

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE